- Home
- KRP vs DYN Comparison
KRP vs DYN Comparison
Compare KRP & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRP
- DYN
- Stock Information
- Founded
- KRP 2013
- DYN 1984
- Country
- KRP United States
- DYN United States
- Employees
- KRP N/A
- DYN N/A
- Industry
- KRP Oil & Gas Production
- DYN Medicinal Chemicals and Botanical Products
- Sector
- KRP Energy
- DYN Health Care
- Exchange
- KRP Nasdaq
- DYN Nasdaq
- Market Cap
- KRP 1.1B
- DYN 1.3B
- IPO Year
- KRP 2017
- DYN 2020
- Fundamental
- Price
- KRP $13.73
- DYN $11.70
- Analyst Decision
- KRP Hold
- DYN Strong Buy
- Analyst Count
- KRP 5
- DYN 12
- Target Price
- KRP $17.40
- DYN $47.00
- AVG Volume (30 Days)
- KRP 521.9K
- DYN 3.2M
- Earning Date
- KRP 05-08-2025
- DYN 05-08-2025
- Dividend Yield
- KRP 12.38%
- DYN N/A
- EPS Growth
- KRP N/A
- DYN N/A
- EPS
- KRP 0.07
- DYN N/A
- Revenue
- KRP $312,627,668.00
- DYN N/A
- Revenue This Year
- KRP $10.43
- DYN N/A
- Revenue Next Year
- KRP $3.44
- DYN N/A
- P/E Ratio
- KRP $191.07
- DYN N/A
- Revenue Growth
- KRP 3.09
- DYN N/A
- 52 Week Low
- KRP $10.98
- DYN $6.36
- 52 Week High
- KRP $17.07
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- KRP 60.76
- DYN 55.43
- Support Level
- KRP $11.83
- DYN $9.17
- Resistance Level
- KRP $14.15
- DYN $13.03
- Average True Range (ATR)
- KRP 0.34
- DYN 1.06
- MACD
- KRP 0.26
- DYN 0.17
- Stochastic Oscillator
- KRP 81.90
- DYN 65.54
About KRP Kimbell Royalty Partners Common Units Representing Limited Partner Interests
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.